These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 21737553)

  • 1. Roflumilast with long-acting β2-agonists for COPD: influence of exacerbation history.
    Bateman ED; Rabe KF; Calverley PM; Goehring UM; Brose M; Bredenbröker D; Fabbri LM
    Eur Respir J; 2011 Sep; 38(3):553-60. PubMed ID: 21737553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
    Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial.
    Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Anzueto A; Alagappan VK; Siddiqui S; Rekeda L; Miller CJ; Zetterstrand S; Reisner C; Rennard SI
    Am J Respir Crit Care Med; 2016 Sep; 194(5):559-67. PubMed ID: 27585384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPD.
    Hanania NA; Calverley PM; Dransfield MT; Karpel JP; Brose M; Zhu H; Goehring UM; Rowe P
    Respir Med; 2014 Feb; 108(2):366-75. PubMed ID: 24120253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease.
    Calverley PM; Sanchez-Toril F; McIvor A; Teichmann P; Bredenbroeker D; Fabbri LM
    Am J Respir Crit Care Med; 2007 Jul; 176(2):154-61. PubMed ID: 17463412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.
    Martinez FJ; Calverley PM; Goehring UM; Brose M; Fabbri LM; Rabe KF
    Lancet; 2015 Mar; 385(9971):857-66. PubMed ID: 25684586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol.
    Calverley PM; Martinez FJ; Fabbri LM; Goehring UM; Rabe KF
    Int J Chron Obstruct Pulmon Dis; 2012; 7():375-82. PubMed ID: 22791991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphodiesterase 4 inhibitors augment the ability of formoterol to enhance glucocorticoid-dependent gene transcription in human airway epithelial cells: a novel mechanism for the clinical efficacy of roflumilast in severe chronic obstructive pulmonary disease.
    Moodley T; Wilson SM; Joshi T; Rider CF; Sharma P; Yan D; Newton R; Giembycz MA
    Mol Pharmacol; 2013 Apr; 83(4):894-906. PubMed ID: 23389862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Roflumilast in combination with long-acting bronchodilators in the management of patients with severe and very severe COPD. A cost-effectiveness analysis for Germany].
    Nowak D; Ehlken B; Kotchie R; Wecht S; Magnussen H
    Dtsch Med Wochenschr; 2013 Jan; 138(4):119-25. PubMed ID: 23322425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roflumilast, a phosphodiesterase-4 inhibitor, induces phagocytic activity in Greek COPD patients.
    Porpodis K; Domvri K; Zarogoulidis P; Petridis D; Tsirgogianni K; Papaioannou A; Hatzizisi O; Kioumis I; Liaka A; Kikidaki V; Lampaki S; Organtzis J; Zarogoulidis K
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1123-8. PubMed ID: 26109853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional respiratory imaging to assess the interaction between systemic roflumilast and inhaled ICS/LABA/LAMA.
    Vos W; Hajian B; De Backer J; Van Holsbeke C; Vinchurkar S; Claes R; Hufkens A; Parizel PM; Bedert L; De Backer W
    Int J Chron Obstruct Pulmon Dis; 2016; 11():263-71. PubMed ID: 26917956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland.
    Samyshkin Y; Schlunegger M; Haefliger S; Ledderhose S; Radford M
    Int J Chron Obstruct Pulmon Dis; 2013; 8():79-87. PubMed ID: 23386787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Common lung conditions: chronic obstructive pulmonary disease.
    Delzell JE
    FP Essent; 2013 Jun; 409():23-31. PubMed ID: 23767419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom.
    Samyshkin Y; Kotchie RW; Mörk AC; Briggs AH; Bateman ED
    Eur J Health Econ; 2014 Jan; 15(1):69-82. PubMed ID: 23392624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roflumilast: a novel treatment for chronic obstructive pulmonary disease.
    Reid DJ; Pham NT
    Ann Pharmacother; 2012 Apr; 46(4):521-9. PubMed ID: 22433610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roflumilast added to triple therapy in patients with severe COPD: a real life study.
    Muñoz-Esquerre M; Diez-Ferrer M; Montón C; Pomares X; López-Sánchez M; Huertas D; Manresa F; Dorca J; Santos S
    Pulm Pharmacol Ther; 2015 Feb; 30():16-21. PubMed ID: 25445930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical profile of roflumilast].
    Izquierdo Alonso JL
    Arch Bronconeumol; 2010 Dec; 46 Suppl 10():25-32. PubMed ID: 21316553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials.
    Calverley PM; Rabe KF; Goehring UM; Kristiansen S; Fabbri LM; Martinez FJ;
    Lancet; 2009 Aug; 374(9691):685-94. PubMed ID: 19716960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial.
    Rabe KF; Bateman ED; O'Donnell D; Witte S; Bredenbröker D; Bethke TD
    Lancet; 2005 Aug 13-19; 366(9485):563-71. PubMed ID: 16099292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can roflumilast, a phosphodiesterase-4 inhibitor, improve clinical outcomes in patients with moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis.
    Luo J; Wang K; Liu D; Liang BM; Liu CT
    Respir Res; 2016 Feb; 17():18. PubMed ID: 26887407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.